Perrigo Co PLC

Exelon's decision to close Three Mile Island seems to be aimed at pressuring Pennsylvania to implement nuclear plant credits. Plus, caution with Perrigo, and HP Enterprise's guidance disappoints.

Increasing competition in the U.S. generics business and past poor capital-allocation decisions diminish our confidence in future economic profits.

Fear could create opportunity, but we advise investors to proceed with caution.

Relatively weak performance from the healthcare sector has created opportunities for long-term investors to consider.

While there was much less conviction buying during the second quarter, our top managers did find a few nuggets.

Ahead of our conversation with Stephen Yacktman, Dennis Lynch, and Michael Keller at the Morningstar Investment Conference, we examine their top holdings and where they are putting money to work today.

The volatility brought on by concerns over global economic growth in the first quarter presented our top managers with both buying and selling opportunities.

Though low earnings multiples are justified for many companies in this beleaguered industry, a handful of players look relatively safe and undervalued at current levels, says Morningstar's Michael Waterhouse.

The stock looks undervalued as accounting issues temporarily detract from an attractive business.

The continuing U.S. stock market rally has diminished the number and similarity of purchases across these top managers.

Recent deals have been driven more by tax strategies than therapeutic synergies.

As the generics wave crests in the coming years, the dynamics of the pharmaceutical industry will change dramatically, say Morningstar's Matt Coffina and Michael Waterhouse.

Stronger-than-expected economic indicators prompted investors to rethink when the Federal Reserve may begin to taper its asset-purchase program.

Favorable conditions are in place for merger-arbitrage ETFs, including increasing M&A activity and the likelihood of higher interest rates.

It's been hard for large-cap funds to succeed without Apple recently, but a handful of funds have.

The large manufacturers shouldn't have much trouble with the new requirements, though.

Google's value to users and advertisers, strong cash-flow generation, and current valuation are attractive, says Sequoia's David Poppe. Plus, Poppe outlines the case for newer fund holding Perrigo.

In the battle between generic and branded biotech, the deck looks increasingly stacked against generics.